Actively Recruiting
Self-Myofascial Release Plus Exercise Versus Exercise Alone in Type 2 Diabetes
Led by Izmir Katip Celebi University · Updated on 2026-02-17
40
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
I
Izmir Katip Celebi University
Lead Sponsor
C
Cigli Regional Training Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This randomized controlled trial aims to investigate the effects of adding self-myofascial release applied to the plantar fascia and gastrosoleus muscles to an exercise program on foot function, physical performance, and plantar fascia thickness in individuals with type 2 diabetes. Participants aged 30 to 65 years with controlled type 2 diabetes will be randomly allocated to either an exercise-only group or an exercise plus self-myofascial release group. Both groups will complete an eight-week supervised exercise program three times per week. The intervention group will additionally perform self-myofascial release using a foam roller before exercise sessions. Outcomes will include foot function, balance, functional mobility, gait performance, and plantar fascia thickness assessed by ultrasonography before and after the intervention.
CONDITIONS
Official Title
Self-Myofascial Release Plus Exercise Versus Exercise Alone in Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged 30 to 65 years
- Diagnosed with type 2 diabetes mellitus for at least 1 year
- Controlled type 2 diabetes mellitus
- Able to ambulate independently without assistive devices
You will not qualify if you...
- Severe pes planus or pes cavus defined by Foot Posture Index-6 (score +10 or -5)
- History of plantar fasciitis
- Plantar fascia ulceration
- Peripheral neuropathy
- Diagnosed peripheral vascular disease
- History of lower extremity surgery or fracture during last year
- Rheumatologic or connective tissue disorders affecting soft tissue
- Neurological or diagnosed cognitive disorders
- Pregnancy
- Other types of diabetes mellitus
- Obesity (BMI > 30 kg/m8)
- Serious cardiopulmonary disorders, including heart failure, myocardial infarction history, or severe COPD or asthma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bakırçay University Çiğli Regional Education Hospital
Izmir, İzmir, Turkey (Türkiye), TR-35620
Actively Recruiting
Research Team
S
Sümena HAREKET KARAKAYA, PT
CONTACT
M
Müge KIRMIZI, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here